Protalix BioTherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 2.59 USD (Oct 30, 2026, 10:12 AM EDT) · Market cap 208.68M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell...